Kevin M Elias Selected Research

Hydatidiform Mole (Molar Pregnancy)

11/2021	Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia.
1/2021	Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression.
1/2020	Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole.
11/2019	State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia.
4/2018	Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
1/2018	Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy.
11/2017	Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
12/2016	Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6months after uterine evacuation?
1/2016	Apoptotic index for prediction of postmolar gestational trophoblastic neoplasia.
11/2015	Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin M Elias Research Topics

Disease

25	Neoplasms (Cancer) 11/2022 - 01/2007
25	Gestational Trophoblastic Disease (Trophoblastic Neoplasms, Gestational) 01/2022 - 05/2010
19	Ovarian Neoplasms (Ovarian Cancer) 06/2022 - 02/2014
10	Hydatidiform Mole (Molar Pregnancy) 11/2021 - 11/2015
8	Ovarian Epithelial Carcinoma 02/2022 - 01/2007
6	Choriocarcinoma 01/2021 - 07/2011
5	Carcinoma (Carcinomatosis) 01/2022 - 05/2010
3	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2018
3	Disease Progression 11/2019 - 05/2010
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2019 - 01/2017
2	Adenocarcinoma 12/2018 - 08/2015
1	Ascites 01/2022
1	Stillbirth 01/2022
1	Spontaneous Abortion (Miscarriage) 01/2022
1	Postoperative Nausea and Vomiting (PONV) 01/2022
1	Cysts 01/2022
1	Hyperthyroidism 01/2022
1	Uterine Hemorrhage (Uterine Bleeding) 01/2021
1	Venous Thromboembolism 01/2021
1	Neutropenia 01/2020
1	Vomiting 01/2019
1	Febrile Neutropenia 01/2019
1	Anemia 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Lymphopenia (Lymphocytopenia) 01/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 09/2018
1	Uterine Perforation 04/2018
1	Infertility (Sterility) 05/2017
1	Ovarian Torsion 05/2017

Drug/Important Bio-Agent (IBA)

11	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 01/2021 - 11/2015
8	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2007
7	PlatinumIBA 11/2022 - 01/2016
7	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 01/2017
6	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2016
5	RNA (Ribonucleic Acid)IBA 11/2022 - 01/2018
5	Proteins (Proteins, Gene)FDA Link 06/2022 - 02/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2018
3	Biological ProductsIBA 01/2022 - 09/2018
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2021 - 01/2016
3	Leucovorin (Folinic Acid)FDA Link 01/2021 - 01/2019
3	Anesthetics (Anesthetic Agents)IBA 12/2015 - 04/2015
2	CA-125 Antigen (CA 125 Antigen)IBA 02/2022 - 01/2022
2	Etoposide (VP 16)FDA LinkGeneric 07/2021 - 01/2019
2	ParaffinIBA 01/2021 - 07/2011
2	Dactinomycin (Actinomycin)FDA LinkGeneric 01/2020 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2018
2	Transcription Factors (Transcription Factor)IBA 08/2016 - 06/2014
1	Morphine (MS Contin)FDA LinkGeneric 01/2022
1	MMEIBA 01/2022
1	LuteinIBA 01/2022
1	Selenoproteins (Selenoprotein)IBA 11/2021
1	Iodide Peroxidase (Deiodinase)IBA 11/2021
1	Local AnestheticsIBA 10/2021
1	Ion Channels (Ion Channel)IBA 10/2021
1	Voltage-Gated Sodium ChannelsIBA 10/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	Growth Differentiation Factor 2IBA 01/2021
1	AntioxidantsIBA 01/2020
1	VitaminsIBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Doxycycline (Periostat)FDA LinkGeneric 11/2019
1	Cisplatin (Platino)FDA LinkGeneric 05/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	Carboplatin (JM8)FDA LinkGeneric 01/2019
1	Indicators and Reagents (Reagents)IBA 04/2018
1	Bevacizumab (Avastin)FDA Link 01/2018
1	EndoglinIBA 01/2018
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	taxaneIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Peptide Nucleic AcidsIBA 01/2018
1	Estradiol (Delestrogen)FDA LinkGeneric 05/2017
1	GonadotropinsIBA 05/2017
1	Interferon Type IIBA 01/2017
1	fludarabineIBA 01/2017
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2016
1	E platinumIBA 01/2016
1	SurvivinIBA 01/2016
1	Caspase 3 (Caspase-3)IBA 01/2016

Therapy/Procedure

21	Drug Therapy (Chemotherapy) 01/2022 - 05/2012
12	Therapeutics 11/2022 - 01/2007
6	Cytoreduction Surgical Procedures 01/2021 - 04/2015
3	Curettage 11/2019 - 05/2010
2	Enhanced Recovery After Surgery 01/2021 - 01/2021
1	Anesthesia 01/2022
1	Immunotherapy 01/2022
1	Treatment Delay 01/2020
1	Hysterectomy 11/2019
1	Aftercare (After-Treatment) 11/2019
1	Brachytherapy 01/2019
1	Ovariectomy (Oophorectomy) 09/2018
1	Gynecologic Surgical Procedures (Gynecologic Surgery) 09/2018
1	Salpingectomy 09/2018
1	Operative Time 01/2018
1	Length of Stay 01/2018
1	Hormonal Contraception 11/2017
1	Tubal Sterilization (Tubal Ligation) 01/2016